Jazz Pharmaceuticals has announced that its experimental lung cancer drug, zanidatamab, did not achieve its primary objective in a pivotal late-stage clinical trial. The drug was being evaluated for its efficacy in treating patients with HER2-positive non-small cell lung cancer (NSCLC), a specific subtype of the disease that can be particularly challenging to treat.
The Phase 3 trial, designed to assess the drug's ability to improve progression-free survival (PFS) – the length of time a patient lives without the disease getting worse – failed to demonstrate a statistically significant benefit compared to existing treatments. This outcome means that zanidatamab is unlikely to progress towards regulatory approval based on these results, potentially closing off a new treatment option for this patient group.
HER2 (human epidermal growth factor receptor 2) is a protein that can be overexpressed in certain cancers, including a subset of lung cancers. While HER2-positive breast cancer has several targeted therapies available, options for HER2-positive lung cancer are more limited. The development of new targeted therapies for NSCLC is a key area of research, given that lung cancer is one of the most common and serious types of cancer in the UK, with around 48,500 new cases diagnosed each year, according to Cancer Research UK.
The failure of a late-stage trial represents a significant setback for both the pharmaceutical company and, more importantly, for patients and clinicians hoping for new therapeutic advancements. Developing new cancer drugs is a complex and often lengthy process, with many promising candidates failing to demonstrate sufficient efficacy or safety in later stages of development. For UK patients, this means that an additional potential treatment may not become available through the NHS in the near future.
According to NHS England data, lung cancer accounts for a significant proportion of cancer-related deaths in the UK. While progress has been made in general lung cancer treatment through immunotherapy and other targeted therapies, specific subtypes like HER2-positive NSCLC still present unmet needs. This trial's outcome underscores the ongoing challenges in finding effective treatments for all forms of the disease.